'UK Strain Is A Whole Virus But Bharat Biotech Vaccine Can Have Edge': Director General Of ICMR
Writer: Pallavi Sharma
Pallavi a post-graduate diploma holder in broadcast journalism is a dance enthusiast who loves to cook, passionate about sketching, takes work and life as it comes with her positive attitude driving them both.
Delhi, 5 Jan 2021 5:44 AM GMT
Editor : Shubhendu Deshmukh |
Shubhendu, the quint essential news junky, the man who loves science and politics in equal measure and offers the complete contrast to it by being a fan of urdu poetry as well.
Creatives : Pallavi Sharma
Pallavi a post-graduate diploma holder in broadcast journalism is a dance enthusiast who loves to cook, passionate about sketching, takes work and life as it comes with her positive attitude driving them both.
On January 3, India gave a nod to the Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin for ‘restricted’ emergency use.
Dr. Balram Bhargava, Director General of Indian Council of Medical Research (ICMR) said that the UK stain is a whole virus and that they hope that Bharat Biotech vaccine will have some advantages over other vaccines on the new strain.
"India-made vaccines target all the proteins on the surface of the virus, not just one S-GEN protein that has mutated. Therefore those vaccines that are targeting just the 'SGEN' may not work as well. But that is still scientific conjecture," said Bhargava.
On January 3, India gave a nod to the Serum Institute of India's Covishield and Bharat Biotech's Covaxin for 'restricted' emergency use.